Evaluation of Serum Lipid Profile after Treatment with Various Chemotherapeutic Scheduals in Iraqi Breast Cancer Patients

Background:Tamoxifen acts as a selective estrogen receptor modulator by binding to the estrogenreceptors on mammary epithelium andblockingtheproliferative action of estrogen on mammaryepithelium. In contrast to that it has a weak estrogen agonistic effect on bone, liver and endometrium.Tamoxifen therapy has favorable effects on serum lipid profile by decreasing serum levels of Total cholesterol and low density lipoprotein (LDL), while its effect on high density lipoprotein (HDL) and triglyceride (TG)is still controversial. So this study is to evaluate the effects of tamoxifenTherapy on fasting serum lipid profile in patients with breast cancer. Results: Mean age was 43.56Ã‚Â±3.53yrs , most common BMI was 30-34.9. Patient serum TG levels were raised from baseline after 3 months of tamoxifen with p values of (0.000) which was statistically significant while HDL levels were raised but with p value of (0.008 ) which was statistically insignificant. Serum LDL and total cholesterol were reduced from baseline after 3 month with p value of (0.000) and (0.000) respectively. Conclusion: This study concludes that tamoxifen has effects on serum lipid profile by increasing TG levels and lowering TC and LDL levels so this should be in consideration while prescribing tamoxifen to the patients having other risk factors for cardiovascular abnormalities.

Download Full-text

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

Breast Cancer Research ◽

10.1186/bcr2320 ◽

2009 ◽

Vol 11 (3) ◽

Cited By ~ 19

Author(s):

Christos Markopoulos ◽

Urania Dafni ◽

John Misitzis ◽

Vasilios Zobolas ◽

Evagelos Tzoracoleftherakis ◽

...

Keyword(s):

Breast Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Hormonal Therapy ◽

Detrimental Effect ◽

Postmenopausal Breast Cancer ◽

Adjuvant Hormonal Therapy ◽

Breast Cancer Patients

Download Full-text

Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving aromatase inhibitors

Journal of Solid Tumors ◽

10.5430/jst.v9n1p11 ◽

2019 ◽

Vol 9 (1) ◽

pp. 11

Author(s):

Reham M. Faheim ◽

Eman A. El-Shaarawy ◽

Dina A. Salem ◽

Rehab G. Shaaban

Keyword(s):

Breast Cancer ◽

Blood Pressure ◽

Lipid Profile ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Postmenopausal Breast Cancer ◽

P Value ◽

Breast Cancer Patients ◽

Hormone Receptor Positive

Background: Aromatase inhibitors (AIs) represent an effective endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients with early stage or metastatic disease.Objective: Assessment of Cardiotoxicity in Hormone positive Postmenopausal Breast Cancer Patients receiving AIs (upfront orswitch therapy).Methods: This cross sectional study included 123 postmenopausal breast cancer patients presented to the Clinical Oncology Department, Ain Shams University (Cairo, Egypt) in the interval from August 2016 to June 2017 with hormone receptor positive receiving Aromatase Inhibitors, To assess cardiotoxicity in these patients, they were subjected to blood pressure and lipid profile measurement, electrocardiography (ECG), and electrocardiography (ECHO) and classified into patients had Nolvadex then A.I (arm 1) and others had upfront A.I (arm 2).Results: The age of patients ranged from 41 years to 85 years with mean age of 61 years. Seventy one patients (57.7%) showed cardiotoxicity as assessed by ECHO. They showed significant correlation with rising age above 62 years, IHD, history of HTN and DM (p value: .001, .001, .017 and 0.035 respectively). However, correlation between cardiotoxity and blood pressure changes, lipid profile changes and ECG findings and ECHO changes in switch therapy and upfront A.I were not statistically significant (p value = .275, .116, .081 and .761 respectively).Conclusion: Assessment of cardiotoxicity in hormone positive postmenopausal breast cancer patients receiving Aromatase Inhibitors showed evidence of cardiotoxicity in half the patients (57.7%) as detected by ECHO only. They showed statistically non significant correlations either recievied switch therapy or upfront A.I.

Download Full-text

Does Adriamycine, Cytoxan with Taxol Treatment Affect FBS and Lipid Profile in Breast Cancer Patients

Archives of Medicine ◽

10.21767/1989-5216.1000166 ◽

2016 ◽

Vol 8 (5) ◽

Author(s):

Simin Hemati ◽

Mansour Siavash Dastjerdi ◽

Minu Jelvan

Keyword(s):

Breast Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Breast Cancer Patients

Download Full-text

111 Hormonal Therapy and Lipid Profile in Breast Cancer Patients

European Journal of Oncology Nursing ◽

10.1016/s1462-3889(12)70123-0 ◽

2012 ◽

Vol 16 ◽

pp. S40

Author(s):

D. Chen ◽

C.H.E. Lin ◽

S.J. Kuo

Keyword(s):

Breast Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Hormonal Therapy ◽

Breast Cancer Patients

Download Full-text

Assessment of Estradiol, Progesterone and Lipid Profile among Breast Cancer Patients in Ethiopia: Hospital-based Comparative Cross-Sectional Study

10.21203/rs.3.rs-966771/v1 ◽

2021 ◽

Author(s):

Etagegn Tadesse ◽

Daniel Seifu ◽

Menakath Menon ◽

Wondmagegnehu Tigeneh ◽

Teka Obsa ◽

...

Keyword(s):

Breast Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Cross Sectional Study ◽

Healthy Controls ◽

Breast Cancer Patients ◽

Sectional Study ◽

Serum Progesterone ◽

Cross Sectional ◽

Progesterone Metabolism

Abstract Background Breast cancer is the most often diagnosed type of cancer and the leading cause of death worldwide. Estrogen, also known as estradiol, influences progesterone metabolism and modifies lipid metabolism. Thus, steroid hormone and lipid profile levels for breast cancer patients must be evaluated. However, this has yet to be explored and used for therapy in Ethiopia. As a result, the present study at Tikur Anbessa Specialized Hospital attempted to assess serum estrogen, progesterone, and lipid profile levels in breast cancer patients and healthy controls. Methods A hospital-based comparative cross-sectional study was conducted on a total of 80 participants (40 newly diagnosed breast cancer patients and 40 healthy control females). A convenient sampling method was used to recruit the study participants. Steroid hormones and lipid profile were determined using immunoassays and an enzymatic colorimetric technique, respectively. SPSS version 20.0 was used for statistical analysis, and p-values of 0.05 were considered statistically significant. Results When compared to healthy controls, the mean serum progesterone, TC, and HDL-C levels in breast cancer patients were considerably lower, while estradiol, TG, and LDL-C levels were insignificantly higher. Conclusions Breast cancer may be to blame for changes in progesterone, estradiol, and lipid profile levels, which can lead to secondary problems.

Download Full-text